Roth Capital Issues Optimistic Forecast for NAGE Earnings

Niagen Bioscience, Inc. (NASDAQ:NAGE) – Analysts at Roth Capital raised their Q2 2026 earnings per share (EPS) estimates for shares of Niagen Bioscience in a note issued to investors on Wednesday, November 5th. Roth Capital analyst S. Mcgowan now expects that the company will post earnings of $0.06 per share for the quarter, up from their prior estimate of $0.04. Roth Capital also issued estimates for Niagen Bioscience’s Q4 2026 earnings at $0.04 EPS, Q1 2027 earnings at $0.11 EPS and Q2 2027 earnings at $0.12 EPS.

A number of other equities research analysts have also weighed in on NAGE. Wall Street Zen lowered shares of Niagen Bioscience from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, September 9th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Niagen Bioscience in a report on Wednesday, October 8th. HC Wainwright increased their target price on Niagen Bioscience from $11.00 to $12.00 and gave the company a “buy” rating in a report on Monday, August 11th. Finally, Canaccord Genuity Group dropped their target price on Niagen Bioscience from $16.00 to $14.00 and set a “buy” rating on the stock in a research report on Wednesday. Four analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $14.28.

Niagen Bioscience Stock Up 3.6%

Shares of Niagen Bioscience stock opened at $6.84 on Thursday. Niagen Bioscience has a twelve month low of $5.16 and a twelve month high of $14.69. The company’s 50 day moving average is $8.35 and its 200 day moving average is $9.73. The company has a market cap of $545.51 million, a price-to-earnings ratio of 32.57 and a beta of 2.16.

Niagen Bioscience (NASDAQ:NAGE) last announced its quarterly earnings results on Tuesday, November 4th. The company reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of $0.02 by $0.03. Niagen Bioscience had a net margin of 15.24% and a return on equity of 23.12%. The firm had revenue of $33.99 million during the quarter, compared to analyst estimates of $31.30 million.

Hedge Funds Weigh In On Niagen Bioscience

Hedge funds have recently modified their holdings of the company. AlphaQuest LLC purchased a new position in shares of Niagen Bioscience in the third quarter valued at $75,000. Versor Investments LP bought a new stake in shares of Niagen Bioscience in the 3rd quarter worth about $432,000. Navellier & Associates Inc. bought a new stake in shares of Niagen Bioscience in the 3rd quarter worth about $1,768,000. Independent Advisor Alliance purchased a new stake in shares of Niagen Bioscience during the 3rd quarter valued at about $227,000. Finally, State of Wyoming bought a new position in shares of Niagen Bioscience in the 3rd quarter valued at about $397,000. 15.41% of the stock is currently owned by institutional investors.

About Niagen Bioscience

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen.